# A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

> **NCT02152371** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 300 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dulaglutide
- **DRUG:** Placebo
- **DRUG:** Insulin Glargine
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02152371
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2019-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02152371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02152371, "A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02152371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*